RMD insider filing: 4,876 common shares planned sale on NYSE
Rhea-AI Filing Summary
ResMed Inc. filed a Form 144 disclosing a proposed sale of 4,876 common shares on the NYSE with an aggregate market value of $1,381,956.16, and 146,414,839 shares outstanding listed. The filing shows the securities were acquired on 10/07/2025 under an option granted 11/16/2022, and the proposed sale date is 10/07/2025. The broker named is Fidelity Brokerage Services LLC in Smithfield, RI. The filer certifies there is no undisclosed material adverse information and reports no securities sold in the past 3 months.
Positive
- Transparent disclosure of the proposed sale under Rule 144 with broker and dates
- No sales in past 3 months, simplifying aggregation rules for this notice
Negative
- Insider sale of 4,876 shares with aggregate value $1,381,956.16 could be viewed negatively by some investors
Insights
TL;DR: Filing documents an insider sale under Rule 144 with clear acquisition and sale dates.
The notice reports a proposed sale of 4,876 common shares via Fidelity Brokerage Services LLC with an aggregate market value of $1,381,956.16. The securities are shown as acquired on 10/07/2025 tied to an option granted 11/16/2022, indicating the sale is linked to option exercise or similar transaction.
Compliance depends on satisfaction of Rule 144 conditions (holding period, public information, volume limits). The signer affirms no undisclosed material adverse information and reports no sales in the past 3 months. Watch for trade settlement and any concurrent Section 16 filings that may be required within the statutory timeframe.